Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG-PEG vs Gamunex-C in Primary Humoral Immunodeficiency
NCT04561115Phase 3Completed
- Sponsor
- Grifols
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of polyethylenglycol-treated gammaglobulin in Primary Humoral Immunodeficiency (2 arms), sponsored by Grifols. Primary endpoints: Area Under the Concentration Time Curve Over a Dosing Interval and Maximum Concentration in a Dosing Interval. Started Sep 2020; status: completed.
02
Drugs
polyethylenglycol-treated gammaglobulin
03
Conditions
Primary Humoral Immunodeficiency
Beyond the preview
Go deeper on NCT04561115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561115.